Risk of Death and Cardiovascular Events Following an Exacerbation of COPD: The EXACOS-CV US Study

References

• Hacker K. COPD Death Rates in the United States. Centers for disease control and prevention. Chronic Obstructive Pulmonary Disease (COPD) Web site; 2021. Available from: https://www.cdc.gov/copd/data.html. Accessed October 18, 2021.
   Google Scholar
• DeBolt CL, Brizendine C, Tomann MM, Harris DA. Lung disease in central Appalachia: it’s more than coal dust that drives disparities. Yale J Biol Med. 2021;94(3):477–486. doi:10.1111/joac.12104
   PubMed Web of Science ®Google Scholar
• Diab N, Gershon AS, Sin DD, et al. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(9):1130–1139. doi:10.1164/rccm.201804-0621CI
   PubMed Web of Science ®Google Scholar
• Martinez CH, Mannino DM, Jaimes FA, et al. Undiagnosed obstructive lung disease in the United States. associated factors and long-term mortality. Ann Am Thorac Soc. 2015;12(12):1788–1795. doi:10.1513/AnnalsATS.201506-388OC
   PubMed Web of Science ®Google Scholar
• Claxton S, Porter P, Brisbane J, et al. Identifying acute exacerbations of chronic obstructive pulmonary disease using patient-reported symptoms and cough feature analysis. Npj Digital Med. 2021;4(1):107. doi:10.1038/s41746-021-00472-x
   PubMed Web of Science ®Google Scholar
• MacIntyre N, Huang YC. Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):530–535. doi:10.1513/pats.200707-088ET
   PubMedGoogle Scholar
• Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to understand prognoses and preferences for outcomes and risks of treatments). Am J Respir Crit Care Med. 1996;154(4 Pt 1):2.
   Web of Science ®Google Scholar
• Donaldson GC, Wedzicha JA. COPD exacerbations 1: epidemiology. Thorax. 2006;61(2):164–168. doi:10.1136/thx.2005.041806
   PubMed Web of Science ®Google Scholar
• Whittaker H, Rubino A, Müllerová H, et al. Frequency and severity of exacerbations of COPD Associated with future risk of exacerbations and mortality: a UK Routine health care data study. Int J Chronic Obstr. 2022;17:427–437. doi:10.2147/COPD.S346591
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553–564. doi:10.1164/rccm.202006-2618OC
   PubMed Web of Science ®Google Scholar
• Mullerova H, Marshall J, de Nigris E, et al. Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis. Ther Adv Respir Dis. 2022;16:17534666221113647. doi:10.1177/17534666221113647
   Web of Science ®Google Scholar
• Terzano C, Conti V, Di Stefano F, et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung. 2010;188(4):321–329. doi:10.1007/s00408-009-9222-y
   PubMed Web of Science ®Google Scholar
• Chenna PR, Mannino DM. Outcomes of severe COPD exacerbations requiring hospitalization. Semin Respir Crit Care Med. 2010;31(3):286–294. doi:10.1055/s-0030-1254069
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Criner GJ, Halpin DMG, et al. Time-dependent risk of cardiovascular events following an exacerbation in patients with chronic obstructive pulmonary disease: post hoc analysis from the IMPACT trial. J Am Heart Assoc. 2022;11(18):e024350. doi:10.1161/JAHA.121.024350
   PubMed Web of Science ®Google Scholar
• Fu X, Zhong Y, Xu W, et al. The prevalence and clinical features of pulmonary embolism in patients with AE-COPD: a meta-analysis and systematic review. PLoS One. 2021;16(9):e0256480. doi:10.1371/journal.pone.0256480
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963. doi:10.1136/thoraxjnl-2011-201518
   PubMed Web of Science ®Google Scholar
• Perera PN, Armstrong EP, Sherrill DL, Skrepnek GH. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD. 2012;9(2):131–141. doi:10.3109/15412555.2011.650239
   PubMedGoogle Scholar
• Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198(1):51–57. doi:10.1164/rccm.201711-2239OC
   PubMed Web of Science ®Google Scholar
• Hu WP, Lhamo T, Zhang FY, et al. Predictors of acute cardiovascular events following acute exacerbation period for patients with COPD: a nested case-control study. BMC Cardiovasc Disord. 2020;20(1):518. doi:10.1186/s12872-020-01803-8
   PubMed Web of Science ®Google Scholar
• Goto T, Shimada YJ, Faridi MK, Camargo CA, Hasegawa K. Incidence of acute cardiovascular event after acute exacerbation of COPD. J Gen Intern Med. 2018;33(9):1461–1468. doi:10.1007/s11606-018-4518-3
   PubMed Web of Science ®Google Scholar
• Swart KA, Baak BN, Lemmens L, et al. Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS‑CV cohort study using the PHARMO Data Network in the Netherlands. Respir Res. 2023;24(1):293. doi:10.1186/s12931-023-02601-4
   PubMed Web of Science ®Google Scholar
• Nordon C, Rhodes K, Quint JK, et al. EXAcerbations of COPD and their OutcomeS on CardioVascular diseases (EXACOS-CV) Programme: protocol of multicountry observational cohort studies. BMJ Open. 2023;13(4):e070022. doi:10.1136/bmjopen-2022-070022
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. National Death Index User’s Guide. Hyattsville, MD: National Center for Health Statistics; 2013.
   Google Scholar
• Rogot E, Sorlie P, Johnson NJ. Probabilistic methods in matching census samples to the National Death Index. J Chronic Dis. 1986;39(9):719–734. doi:10.1016/0021-9681(86)90155-4
   PubMedGoogle Scholar
• Zhang J, Zheng J, Huang K, Chen Y, Yang J, Yao W. Use of glucocorticoids in patients with COPD exacerbations in China: a retrospective observational study. Ther Adv Respir Dis. 2018;12:1753466618769514. doi:10.1177/1753466618769514
   Web of Science ®Google Scholar
• Schacht A, Bogaerts K, Bluhmki E, Lesaffre E. A new nonparametric approach for baseline covariate adjustment for two-group comparative studies. Biometrics. 2008;64(4):1110–1116. doi:10.1111/j.1541-0420.2008.00994.x
   PubMed Web of Science ®Google Scholar
• Stuart EA, Lee BK, Leacy FP. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J Clin Epidemiol. 2013;66(8 Suppl):S84–S90.e81. doi:10.1016/j.jclinepi.2013.01.013
   PubMed Web of Science ®Google Scholar
• U.S. Census Bureau. 2013–2017 American Community Survey 3-year Public Use Microdata Samples. U.S. Census Bureau, ed. guides.library.duq.edu/c.php?g=753544&p=5401552: U.S. Census Bureau; 2012.
   Google Scholar
• Kostikas K, Loefroth E, Fogel R, et al. Clinical consequences of late Chronic Obstructive Pulmonary Disease (COPD) diagnosis compared to early diagnosis in UK primary care. Eur Respirat J. 2019;54(suppl 63):PA2497.
   Google Scholar
• Huang Q, Xiong H, Shuai T, et al. Risk factors for new-onset atrial fibrillation in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. PeerJ. 2020;8:e10376. doi:10.7717/peerj.10376
   PubMed Web of Science ®Google Scholar
• Chaudhary N, Khan UH, Shah TH, et al. Prevalence and predictors of pulmonary embolism in patients with acute exacerbation of chronic obstructive pulmonary disease. Lung India. 2021;38(6):533–539. doi:10.4103/lungindia.lungindia_79_21
   PubMed Web of Science ®Google Scholar
• Baldomero AK, Kunisaki KM, Bangerter A, et al. Beyond access: factors associated with spirometry underutilization among patients with a diagnosis of COPD in Urban tertiary care centers. J COPD Foundation. 2022;9(4):538–548. doi:10.15326/jcopdf.2022.0303
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease I. Pocket Guide to COPD Diagnosis, Management, and Prevention, a Guide for Health Care Professionals. Global Initiative for Chronic Obstructive Lung Disease, Inc; 2023.
   Google Scholar
• Hui S, How CH, Tee A. Does this patient really have chronic obstructive pulmonary disease? Singapore Med J. 2015;56(4):194–196. doi:10.11622/smedj.2015058
   PubMed Web of Science ®Google Scholar
• Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516. doi:10.1164/rccm.201911-2207OC
   PubMed Web of Science ®Google Scholar
• Chen H, Deng ZX, Sun J, et al. Association of inhaled corticosteroids with all-cause mortality risk in patients with COPD: a meta-analysis of 60 randomized controlled trials. Chest. 2023;163(1):100–114. doi:10.1016/j.chest.2022.07.015
   PubMed Web of Science ®Google Scholar
• Montero A, Kearney A, Hamel L, Brodie M American’ challenges with health care costs. Kaiser Family Foundation 2022;Health Costs 12; 2022.
   Google Scholar
• Chen J, Rizzo JA, Rodriguez HP. The health effects of cost-related treatment delays. Am J Med Qual. 2011;26(4):261–271. doi:10.1177/1062860610390352
   PubMed Web of Science ®Google Scholar
• Abelson R Higher bills are leading Americans to delay medical care The New York Times 2023;Health; 2023.
   Google Scholar
• Larsen DL, Gandhi H, Pollack M, Feigler N, Patel S, Wise RA. The quality of care and economic burden of COPD in the United States: considerations for managing patients and improving outcomes. Am Health Drug Benefits. 2022;15(2):57–64.
   Web of Science ®Google Scholar
• Kerr M, Tarabichi Y, Evans A, et al. Patterns of care in the management of high-risk COPD in the US (2011–2019): an observational study for the CONQUEST quality improvement program. Lancet Region Health Am. 2023;24:100546. doi:10.1016/j.lana.2023.100546
   PubMedGoogle Scholar